Evidence map›Paper›PMID 26612755›Full record

ArticlePathology oncology research : POR2016

RRM1, ERCC1 and TS1 Immunofluorescence Expression in Leiomyosarcoma: A Tissue Microarray Study with Clinical Outcome Correlation Analysis.

Sam D Zheng, Katherine Bui, Alberto Chiappori, Gerold Bepler, Marilyn M Bui

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathology oncology research : POR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Sam D ZhengMorsani College of Medicine, University of South Florida, Tampa, FL, USA.
Katherine BuiMorsani College of Medicine, University of South Florida, Tampa, FL, USA.
Alberto ChiapporiDepartment of Pathology, Thoracic Oncology, H. Lee Moffitt Cancer Center, MCC 2nd FL, 12029 Magnolia Drive, Tampa, FL, 33647, USA.
Gerold BeplerKarmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
Marilyn M BuiDepartment of Pathology, Thoracic Oncology, H. Lee Moffitt Cancer Center, MCC 2nd FL, 12029 Magnolia Drive, Tampa, FL, 33647, USA. marilyn.bui@moffitt.org.
Moffitt Cancer Center · USUniversity of South Florida · USWayne State University · US

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5M
Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI PAUL M STEMMER · 1985 to 2026
$68.4M
NCI NIH HHS P30 CA022453NCI NIH HHS P30 CA076292
6 · The paper itself

Abstract

unlabelledERCC1, RRM1 and TS1 are reportedly linked to chemotherapy resistance in lung and other cancers. However, there are currently no studies reporting the relationship between these genes and clinical parameters in leiomyosarcomas.

methodThis study investigated the expression pattern of ERCC1, RRM1 and TS1 in forty-four leiomyosarcoma samples by the use of tissue microarray (TMA), immunofluorescence and AQUA methods. The results were then analyzed for expression level and correlations were made with clinical outcome to determine their potential prognostic value in leiomyosarcoma.

resultsIn the forty-four samples studied, the expression level of these three proteins can be well quantified in the AQUA system and reflected by the AQUA score. RRM1 and ERCC1 expression levels did not show any relationship with overall survival. However, a correlation was found between TS1 expression in the cytoplasm and overall survival. The high expression group had a shorter overall survival time (log-rank p = 0.0498). This trend was confirmed by the Cox proportional hazards model. DISCUSSION: The poor overall survival of leiomyosarcoma is linked to TS1 cytoplasm expression which may be useful in predicting prognoses of this tumor, methods targeting expression of TS1 may lead to improved overall survival in leiomyosarcoma, though more detailed information regarding treatment information and a larger sample size is needed to confirm this phenomenon.

Indexed as

Biomarkers, TumorCytoplasmDNA-Binding ProteinsEndonucleasesFemaleFluorescent Antibody TechniqueHumansLeiomyosarcomaMaleMiddle AgedPrognosisRetrospective StudiesRibonucleoside Diphosphate ReductaseTissue Array AnalysisTumor Suppressor ProteinsBiomarkers, TumorDNA-Binding ProteinsEndonucleasesERCC1 protein, humanRibonucleoside Diphosphate ReductaseRRM1 protein, humanTumor Suppressor ProteinsERCC1LeiomyosarcomaPrognosisRRM1Soft tissue tumorSurvivalTissue microarrayTS1

Identifiers

PMID26612755
PMCPMC6863146
OpenAlexW2257690489

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.